Whitehall-Robins' vitamin/mineral/herbal combination product increases levels of plasma vitamin E, folic acid and vitamin B12, M.H. Davidson, Chicago Center for Clinical Research, et al., report in poster to be presented at Federation of American Societies for Experimental Biology meeting in Orlando, Fla. March 31 to April 4. Results of the 12-week, double-blind, placebo-controlled study involving 161 people indicate "key nutrients are well absorbed from this formulation, which improved cardiovascular risk factors [such as] elevated homocysteine and low density lipoprotein susceptibility to oxidation," researchers conclude. Homocysteine levels decreased 17.2% in active arm compared to mean increase of 3.2% in placebo arm. Centrum Heart Focused Formula contains vitamins B6, B12 and E, folate, selenium, manganese, garlic powder, taurine and coenzyme Q10. Study was funded in part by Whitehall-Robins
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A 26 June deadline looms for the final guidance even though a draft guidance was removed from the agency’s website to comply with President Trump’s gender ideology executive order. The concepts underpinning the guidance are still relevant, legal experts say.
Pink Sheet reporter and editors discuss CBER Director Vinay Prasad’s expectation to stay out of routine application decisions, despite the agency’s top-down leadership approach, and the extent of proposed FDA budget cuts.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
